Agreements reached under this partnership
Business alliance- 1
Exclusive distribution agreement in Japan
- 2
The Company aims to obtain reimbursement listing following regulatory approval.
- 3
The Company plans to begin direct sales to hospitals and other medical institutions through 朝日インテック J セールス株式会社.
These are items that the documents state the two companies will work on. The lines above and below represent arrangements between the two companies.
This matter will have no impact on the Company Group’s consolidated results for the current fiscal year.
| Item | Details |
|---|---|
| Name of alliance partner | NEXTBIOMEDICAL CO., LTD. |
| Alliance partner's business activities | Development and manufacture of medical devices, including endoscopic hemostatic materials and embolic agents |
| Alliance partner's location | Incheon Metropolitan City, South Korea |
| Type of alliance | Business alliance |
| Details of the alliance | Exclusive distribution agreement in Japan, The Company aims to obtain reimbursement listing following regulatory approval., The Company plans to begin direct sales to hospitals and other medical institutions through 朝日インテック J セールス株式会社. |
| Contract Period | Five years following reimbursement listing in Japan. Annual renewal is expected thereafter. |
| Date of board resolution | 9 April 2026 |
| Contract Date | 9 April 2026 |
| Alliance start date | Scheduled to begin following regulatory approval and reimbursement listing |
| Impact on Business Performance | This matter will have no impact on the Company Group’s consolidated results for the current fiscal year. |
Items this document does not state (13)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The Company expects to promote the adoption of the product by leveraging the relationships it has built with physicians, its product development capabilities and its sales network, as well as to generate synergies with related products of the Company’s Group. The Company also aims to expand the potential of TAME as a new treatment option and contribute to improving patients’ quality of life.